ArticleCureus2025
Giant Cell Arteritis Manifesting as Area Postrema Syndrome: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A 76-year-old man presenting with intractable nausea, vomiting and hiccoughs was found to have multiple watershed cerebellar strokes and a medullary stroke involving the area postrema. Imaging revealed extensive segmental stenoses involving the bilateral V2-V3 portions of the vertebral arteries. Mildly elevated inflammatory markers raised the possibility of giant cell arteritis (GCA). While the patient exhibited multiple neurological deficits, it was his intractable nausea, vomiting and hiccoughs - manifestations of area postrema syndrome (APS) - that prolonged his admission to a total of 81 days, limiting his ability to engage with rehabilitation. The diagnosis was confirmed with positron emission tomography (PET) imaging. Treatment with corticosteroids was initiated, followed by the introduction of weekly subcutaneous tocilizumab, an IL-6 inhibitor, ultimately resolving both his APS and its underlying cause, giant cell arteritis. To our limited knowledge, this is only the second case of area postrema syndrome caused by GCA in the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.